|Table of Contents|

Chemoradiotherapy combined with radiofrequency ablation in locally advanced non-small cell lung cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2018 06
Page:
884-887
Research Field:
Publishing date:

Info

Title:
Chemoradiotherapy combined with radiofrequency ablation in locally advanced non-small cell lung cancer
Author(s):
Cui Lin; Chen Jue; Liu Jianjun; Qian Houlong; Liu Xingxiang; Jiang Yong; Chen Gaoyang; Wu Xingjun; He Xuejun
Department of Oncology,Taizhou Second People's Hospital,Jiangsu Taizhou 225500,China.
Keywords:
non-small cell lung cancer; radiotherapy; chemotherapy; radiofrequency ablation
PACS:
R734.2
DOI:
10.3969/j.issn.1672-4992.2018.06.017
Abstract:
Objective:To evaluate the curative effect and safety of chemoradiotherapy combination with radiofrequency ablation in locally advanced non-small cell lung cancer.Methods:According to the researching principles,76 matched patients were randomly devided into two arms,the observation group(OG) and the control group(CG).In the OG,chemoradiotherapy and radiofrequency ablation were used synergisticly while in the CG ablation was absent.Results:In the OG(40 cases),response rate(RR) was 65.0%,disease control rate(DCR) was 77.5%,while those were 30.6% and 55.6% respectively in CG.A signficant difference was found between the two groups(P=0.006，P=0.041).The common side-reactions were associated with the chemotherapy and RAF.Hemoptysis,bloody spatum,faver and aerothorax were occasionally observed and could be corrected using corresponding treatments.In OG,the mean overall-survival was (15.8±2.6) months,it was (18.9±2.8) months in IIIa patients and (14.2±1.9) months in IIIb patients.As the control,the mean OS was (13.4±2.3) months,it was (15.2±2.6) months in IIIa subgroup and (12.3±1.7) months in IIIb subgroup.Only IIIa patients in OG showed a survival advantage compared with those IIIa patients in CG(P=0.039).In OG,progression free survival(PFS) was (11.8±3.6) months in IIIa patients and (8.1±1.2) months in IIIb patients,the mean PFS was (9.9±2.8) months.In CG,PFS was （8.9±3.4） months in IIIa patients and （6.4±1.5） months in IIIb patients,the mean PFS was （8.7±2.2） months.Only patients with IIIa staging in OG showed a PFS advantage(P=0.044).Quality of life(QOL) was improved in two groups.However,only IIIb patients received synergistic treatment showed significant improvement in QOL(P=0.038).Conclusion:RAF combination with chemoradiotherapy can prolong OS and PFS in lung cancer patients with IIIa staging and improve the QOL in patients with IIIb staging.

References:

[1]Wei Ying,Li Zheng,Mi Denghai,et al.A systematic review of radiotrequency ablation combined with radiotherapy or chemotherapy in the treatment of advanced non-small cell lung cancer［J］.Modern Oncology,2015,23(18):2609-2614.［韦英，李征，米登海，等.射频消融联合放化疗治疗中晚期非小细胞肺癌的系统评价［J］.现代肿瘤医学，2015,23(18):2609-2614.］
[2]Zou Xugong,Li Xiaoqun.Radiofrequency ablation for the treatment of malignant pulmonary cancer:Current clinical situation［J］.J lntervent Radio,2016,25(7):646-650［邹旭公，李晓群.肺恶性肿瘤射频治疗现状［J］.介入放射学杂志,2016,25(7):646-650.］
[3]Andoh H，McNulty NJ，Lewis PJ．Improving accuracy in reporting CT scans of oncology patients:Assessing the effect of education and eeedback interventions on the application of the response evaluation criteria in solid tumors(RECIST) criteria［J］.Acad Radiol，2013，20(3):351－357．
[4]Jiang Ming,Hu Hongtao.Imaging effects,complications and survival of 76 patients with lung cancer treated by CT guided radiofrequency ablation［J］.China Journal of CT and MRI,2017,15(7):30-32.［蒋明，胡鸿涛.CT引导下射频消融治疗肺癌76例的影像学、并发症及存活情况分析［J］.中国CT和MRI杂志,2017,15(7):30-32.］
[5]Trotti A，Byhardt R，Stetz J，et al．Common toxicity criteria:Version 2.0:An improved reference for grading the acute effects of cancer treatment:Impact on chemotherapy［J］.Int J Radiat Oncol Biol Phys，2000，47(1):13－47．
[6]Byhardt RW，Scott C，Sause WT，et al．Response，toxicity，failure patterns，and survival in five Radiation Therapy Oncology Group(RTOG) trials of sequential and /or concurrent chemotherapy and radiotherapy for locally advanced non－small cell carcinoma of the lung［J］.Int J Radiat Oncol Biol Phys，1998，42(3):469－478．
[7]Siegel R,Ma J，Zou Z,et al.Cancer statistics［J］.CA Cancer J Clin,2014，64(1):9-29.
[8]She J,Yang P,Hong Q,et al.Lung cancer in China:Challenges and interventions［J］.Chest,2013,143(4):1117-1126.
[9]Dupuy DE，Zagoria RJ，Akerley W，et al．Percutaneous radio frequency ablation of malignancies in the lung［J］.AJR，2000，74:57－59．
[10]Liu Baodong,Zhi Xiuyi.Expert consensus for image-guided radiofrequency ablation of pulmonary tumors［J］.Chin J Lung Cancer,2015,18(5):251-259.［刘宝东，支修益.影像引导射频消融治疗肺部肿瘤专家共识(2015年版)［J］.中国肺癌杂志，2015,18(5):251-259.］
[11]Liu Wei,Wang Ying.Recent state in radiofrequency ablation of lung cancer［J］.Journal of Clinical Medical,2017,4(36):7125-7128.［刘炜，王莹.肺癌射频消融治疗的近况［J］.临床医药文献杂志,2017,4(36):7125-7128.］
[12]Wang Jidong,Yan Xueqing,Wang Junjie.The research progress of non-surgical treatment of early lung cancer［J］.Onclogy Progress,2016,14(7):623-627.［王济东，颜学庆，王俊杰.早期肺癌局部非手术治疗的研究进展［J］.癌症进展,2016,14(7):623-627.］
[13]Kim SR,Han HJ,Park SJ,et al.Comparison between surgery and radiofrequency ablation for stage Ⅰnon-small cell lung cancer［J］.Eur J Radiol,2012,81(2):395-399.
[14]Bott MJ,Crabtree T.Treatment of stageⅠlung cancer in high-risk and inoperable patients:SBRT vs RFA vs sublobar resection［J］.Ann Cardiothorac Surg,2014,3(2):167-169.
[15]Hiraki T,Gobara H,Mimura H,et al.Percutaneous radiofrequency ablation of clinical stageⅠnon-small cell lung cancer［J］.Cardiovasc Surd,2011，142(1):24-30.
[16]Lee H,Jin GY,Han YM,et al.Comparison of survival rate in primary non-small-cell lung cancer among elderly patients treated with radiofrequency ablation,surgery,or chemotherapy［J］.Cardiovasc Intervent Radiol,2012,35(2):343-350.
[17]Dupuy DE,Fernando HC,Hillman S,et al.Radiofrequency ablation of stage Ⅰa non-small cell lung cancer in medically inoperable patients:Results from the American college of surgeons oncology group Z4033(Alliance) trial［J］.Brachytherapy,2011,10(3):253-259.
[18]Sun Denghua,Qian Feng,Sun Guang,et al.Clinical applications of radiofrequency ablation［J］.Jilin Medical Journal,2012,33(13):2823-2825.［孙登华，钱锋，孙光，等.射频消融技术的临床应用进展［J］.吉林医学，2012,33(13):2823-2825.］
[19]Liu Wenjing,Zeng Xiantao，Liu Xiaoqing,et al.Radiofrequency ablation and chemotherapy combination versus chemotherapy monotherapy in non-small cell lung cancer:A systematic review of meta analysis［J］.Chin Clin Oncol,2012,17(6):530-538.［刘文静，曾宪涛，刘晓晴，等.射频消融联合化疗治疗晚期非小细胞肺癌疗效的Meta分析［J］.临床肿瘤学杂志，2012,17(6):530-538.］
[20]Zhu Yonggang,Zhou Chengwei,Lu Bin,et al.Short-term efficacy of radiofrequency ablation combined with chemotherapy for locally advanced non-small cell lung cancer［J］.Modern Practical Medicine,2014，26（7）：829-830.［朱勇刚，周成伟，卢斌，等.射频消融联合化疗治疗局部晚期非小细胞肺癌近期疗效观察［J］.现代实用医学，2014，26（7）：829-830.］
[21]Wang Meiyun,Ying Xing,Hou Yongchao,et al.The Effects of radiofrequency ablation combined with chemotherapy and chemoradiotherapy synchronous sequential treatment for local advanced non-small cell lung cancer on quality of life［J］.Med & Pharm J China PLA,2016，28（6）：46-48.［王梅云，殷星，候永超，等.射频消融术联合同步放化疗并序贯化疗治疗中晚期局部非小细胞肺癌对患者生存质量的影响［J］.解放军医药杂志，2016，28（6）：46-48.］
[22]Deng Lingbo，Li Xiaoguang，Ming Weidi.Radiofrequency ablation for the treatment of advanced non-small-cell lung cancer:A meta-analysis［J］.Journal of Interventional Radiology,2013,22(12):1000-1006.［邓灵波，李晓光，明韦迪.射频消融治疗晚期非小细胞肺癌疗效的荟萃分析［J］.介入放射学杂志,2013,22(12):1000-1006.］
[23]Zhou Jingxu,Li Hong,Lv Wenjiao,et al.Curative effect of radiofrequency ablation combined with chemotherapy on middle-late stage non-small cancer［J］.The Journal of Practical Medicine,2015,31(11):1786-1789.［周京旭，李虹，吕文娇，等．经皮射频消融联合化疗治疗IIIb-IV期非小细胞肺癌的疗效［J］.实用医学杂志,2015,31(11):1786-1789.］

Memo

Memo:
江苏大学医学临床科技发展基金资助（编号：JLY20160162）
Last Update: 2018-01-29